X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs GLENMARK PHARMA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER GLENMARK PHARMA PFIZER/
GLENMARK PHARMA
 
P/E (TTM) x 32.0 17.7 181.0% View Chart
P/BV x 5.1 3.1 161.4% View Chart
Dividend Yield % 0.7 0.3 201.0%  

Financials

 PFIZER   GLENMARK PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-18
GLENMARK PHARMA
Mar-18
PFIZER/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs2,365930 254.3%   
Low Rs1,625517 314.1%   
Sales per share (Unadj.) Rs430.3322.6 133.4%  
Earnings per share (Unadj.) Rs78.728.5 276.3%  
Cash flow per share (Unadj.) Rs93.239.2 237.8%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %1.00.3 362.8%  
Book value per share (Unadj.) Rs586.5183.0 320.5%  
Shares outstanding (eoy) m45.75282.17 16.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.62.2 206.7%   
Avg P/E ratio x25.325.4 99.8%  
P/CF ratio (eoy) x21.418.5 115.9%  
Price / Book Value ratio x3.44.0 86.0%  
Dividend payout %25.47.0 362.0%   
Avg Mkt Cap Rs m91,271204,206 44.7%   
No. of employees `0002.613.7 19.2%   
Total wages/salary Rs m3,14318,718 16.8%   
Avg. sales/employee Rs Th7,484.86,636.8 112.8%   
Avg. wages/employee Rs Th1,195.01,364.7 87.6%   
Avg. net profit/employee Rs Th1,369.1586.1 233.6%   
INCOME DATA
Net Sales Rs m19,68591,031 21.6%  
Other income Rs m1,143914 125.0%   
Total revenues Rs m20,82891,945 22.7%   
Gross profit Rs m5,00316,154 31.0%  
Depreciation Rs m6633,019 21.9%   
Interest Rs m42,856 0.1%   
Profit before tax Rs m5,47911,193 48.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8783,155 59.5%   
Profit after tax Rs m3,6018,039 44.8%  
Gross profit margin %25.417.7 143.2%  
Effective tax rate %34.328.2 121.6%   
Net profit margin %18.38.8 207.1%  
BALANCE SHEET DATA
Current assets Rs m24,16769,887 34.6%   
Current liabilities Rs m9,54432,879 29.0%   
Net working cap to sales %74.340.7 182.7%  
Current ratio x2.52.1 119.1%  
Inventory Days Days5581 67.7%  
Debtors Days Days2993 30.7%  
Net fixed assets Rs m9,51428,892 32.9%   
Share capital Rs m458282 162.1%   
"Free" reserves Rs m26,37551,353 51.4%   
Net worth Rs m26,83251,635 52.0%   
Long term debt Rs m2541,418 0.1%   
Total assets Rs m36,900125,954 29.3%  
Interest coverage x1,305.54.9 26,537.5%   
Debt to equity ratio x00.8 0.1%  
Sales to assets ratio x0.50.7 73.8%   
Return on assets %9.88.6 112.9%  
Return on equity %13.415.6 86.2%  
Return on capital %20.415.1 135.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m2236,317 0.1%   
Fx outflow Rs m1,4899,720 15.3%   
Net fx Rs m-1,46626,598 -5.5%   
CASH FLOW
From Operations Rs m3,31816,481 20.1%  
From Investments Rs m-2,383-10,133 23.5%  
From Financial Activity Rs m-1,104-4,685 23.6%  
Net Cashflow Rs m-1691,770 -9.5%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 6.9 108.7%  
FIIs % 4.9 34.4 14.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 10.5 225.7%  
Shareholders   85,207 56,727 150.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  CADILA HEALTHCARE  AUROBINDO PHARMA  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Flat; Realty and Auto Stocks Gain(12:30 pm)

Share markets in India are presently trading on a flat note. Sectoral indices are trading mixed with stocks in the banking sector and energy sector.

Related Views on News

PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)

Jan 25, 2019 | Updated on Jan 25, 2019

For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Feb 12, 2019

Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.

The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)

Feb 15, 2019

Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Feb 22, 2019 01:23 PM

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS